mProX™ Human NTRK2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human NTRK2 Stable Cell Line (S01YF-1023-PY118). Click the button above to contact us or submit your feedback about this product.
Taylor Jones (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Skyler Johnson (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The synergistic impact of PTEN depletion and NTRK2 activation on the modulation of the PI3K/AKT and STAT3 signaling cascades was investigated, emphasizing the passive construction of the research article.
The increased activation of PI3K/mTOR and STAT3 was assessed through RPPA assay in Ba/F3 cells, with cells from Ba/F3-shCTRL-EV, shCTRL-NTRK2-Tel, shPTEN-EV, and shPTEN-NTRK2-Tel being lysed and subjected to reverse phase protein array analysis in the left panel. In the right panel, analysis of AKT and STAT3 signaling in Ba/F3 cells was conducted as indicated. Quantification of P-AKT and P-STAT3 was normalized to total AKT or total STAT3 levels through immunoblotting.
Ref: Yuzugullu, Haluk, et al. "NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways." Cell discovery 2.1 (2016): 1-13.
Pubmed: 27672444
DOI: 10.1038/celldisc.2016.30
Research Highlights
Lin, Ruihe. et al. "Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy." Diagnostic pathology, 2023.
NTRK2, one of three NTRK genes, displays significant structural complexity and has been linked to the development of various tumor types. Current research has identified only STRN and RBPMS as fusion partners with NTRK2 in adult soft tissue tumors. The FDA has recently approved two highly selective Trk tyrosine kinase inhibitors, larotrectinib and entrectinib, which have demonstrated notable success in treating tumors with NTRK fusions. These findings highlight the importance of NTRK2 in tumorigenesis and suggest promising treatment options for affected individuals.
Lin, Ruihe. et al. "Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy." Diagnostic pathology, 2023.
Pubmed:
37865792
DOI:
10.1186/s13000-023-01400-1
Donati, Michele. et al. "Spitz tumor with RAF1 fusion: A report of 3 cases." Annals of diagnostic pathology, 2023.
The morphological and molecular characteristics of Spitz tumors suggest that they are melanocytic neoplasms. These tumors exhibit spindled and/or epithelioid cells and unique stromal and epidermal changes associated with fusion kinases. Mutations in genes such as ALK, ROS1, NTRK1, NTRK2, NTRK3, MET, RET, BRAF, MAP3K8, and HRAS have been identified in these tumors. Recently, the presence of RAF1 fusions has been observed in cutaneous melanocytic neoplasms, including conventional melanoma, congenital nevus, and BAP-1 inactivated tumors. In this study, the authors present three cases of Spitz neoplasms with RAF1 fusions, including a previously reported CTDSPL::RAF1 fusion and two novel PPAP2B::RAF1 and ATP2B4::RAF1 fusions. While two of the cases were classified as Spitz nevus, the third case was initially diagnosed as Spitz melanoma due to 9p21 homozygous deletion and positive sentinel lymph node biopsy. The authors propose that RAF1 fused melanocytic neoplasms may represent a distinct subset of Spitz tumors with RAF1 fusion as an oncogenic driver.
Donati, Michele. et al. "Spitz tumor with RAF1 fusion: A report of 3 cases." Annals of diagnostic pathology, 2023.
Pubmed:
37856952
DOI:
10.1016/j.anndiagpath.2023.152215
